New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)-Reference-Cited by-同舟云学术

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

Published:2020-04-16 Issue:5 Volume:22 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Russo Alessandro,Lopes Ana Rita,McCusker Michael G.,Garrigues Sandra Gimenez,Ricciardi Giuseppina R.,Arensmeyer Katherine E.,Scilla Katherine A.,Mehra Ranee,Rolfo Christian

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11912-020-00909-8.pdf

Reference128 articles.

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

3. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19:4532–40.

4. Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015;121:448–56.

5. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574–9.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

2. Novel therapeutic strategies for rare mutations in non-small cell lung cancer;Scientific Reports;2024-05-05

3. SCUBE3 Exerts a Tumor-Promoting Effect in Tongue Squamous Cell Carcinoma by Promoting CEBPA Binding to the CCL2 Promoter;Molecular Cancer Research;2024-02-13

4. Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer;European Journal of Medicinal Chemistry;2023-12

5. Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC;Journal of Medicinal Chemistry;2023-05-04